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HE PATHOGENESIS OF INFLA-
mmatory bowel disease (IBD)
is thought to be multifactorial,
involving a genetically suscep-
tible individual being exposed to a yet-
to-be identiﬁed environmental trigger
or set of triggers. There is growing evi-
dence that IBD may be a disease of
Westernization associated with diets
high in reﬁned sugars; bread and ce-
reals; proteins, especially dairy; and
n-6 polyunsaturated fatty acids ac-
quired from highly processed seed oils.
However, the evidence is often low
quality, conﬂicting, and inconclusive.1-5
The Speciﬁc Carbohydrate Diet
(SCD) is a dietary program that claims
to induce and maintain drug-free
remission in patients with IBD. It was
initially developed by gastroenterolo-
gist Sidney Haas in 1951 and later
popularized by biochemist Elaine
Gottschall in the book Breaking the
Vicious Cycle: Intestinal Health Through
Diet.6,7 The diet allows carbohydrate
foods consisting of monosaccharides
only and excludes disaccharides and
most polysaccharides (such as linear
or branch-chained multiple sugars or
starches). The diet is supplemented by
homemade yogurt fermented for 24
hours to free it of lactose, a disaccha-
ride not allowed in the SCD. Recom-
mended cultures include Lactobacillus
bulgaricus, Lactobacillus acidophilus,
and Streptococcus thermophilus. ThehttSCD allows almost all fruits, vegeta-
bles containing more amylose (a
linear-chain polysaccharide) than
amylopectin (a branch-chained poly-
saccharide), nuts, nut-derived ﬂours,
dry-curd cottage cheese, meats, eggs,
butters, and oils. It excludes sucrose,
maltose, isomaltose, lactose, grain-
derived ﬂours and all true and pseu-
dograins, potatoes, okra, corn, ﬂuid
milk, soy, cheeses containing high
amounts of lactose, as well as most
food additives and preservatives. The
typical starting dieter begins eating
foods that are thought to be well
tolerated, including cooked, peeled,
and seeded fruits and vegetables, and
over time other foods are added
slowly to partially liberalize the diet.
The SCD is not a low-carbohydrate
diet, but rather a diet that is predomi-
nantly composed of monosaccharaides,
solid proteins, fats, a high ratio of
amylose to amylopectin vegetables,
fruits, and nuts. Gottschall7 hypothe-
sized that patients with IBD can only
optimally absorb the monosaccharides
glucose, galactose, and fructose due
to a dysfunction of the host’s di-
saccharidases that are necessary
for digestion and absorption of di-
saccharides and high amylopectin
foodstuffs. This dysfunction is posited
to arise from excessive mucus produc-
tion preventing the brush border in-
testinal enzymes from making contact
with the disaccharidases and amylo-
pectin causing maldigestion. Further,
toxic substances produced by dysbiosis
of the luminal microbiota (eg, the
overgrowth of yeast and bacteria) in
the small intestine may cause damage
to intestinal cell membranes and
destroy brush boarder enzymes.7 A diet
containing carbohydrate from primar-
ily monosaccharide sources such as
fructose (as in fruits and honey) and
higher amylose:amylopectin vegeta-
bles, butter or oils, and solid proteins
could optimally nourish a patient with015 by the Academy o
le under the CC B
ses/by-nc-sa/4.0/).IBD and result in lower amounts of
disaccharide sugars entering the colon,
preventing and reversing a signiﬁ-
cantly altered and dysfunctional
microbiota postulated to be present in
the gastrointestinal tract of patients
with IBD.7
Neither the characteristics of pa-
tients who are following the SCD nor
the beneﬁts of this diet have been well
described in the medical literature.
Herein, we report on the largest series
of patients with IBD following the SCD
to date and describe their clinical
characteristics.PATIENT OVERVIEW
We collected survey data from pa-
tients with IBD following the SCD
living within the continental United
States. Subjects were recruited
through advertisements posted on
SCD message boards and websites as
well as through our own gastroenter-
ology clinics. Subjects mailed their
medical records and ﬁlled out a
structured survey of their medical
history, a 3-day diet diary, and a vali-
dated disease activity index. The
modiﬁed Harvey-Bradshaw Index was
used for Crohn’s disease (CD),8 the St
Mark’s Index was used for ulcerative
colitis (UC),9 and both indexes were
used for cases of indeterminate colitis
(ID). Presence of gastrointestinal
symptoms within 1 week of the data
collection was assessed with the use
of a structured survey called the
Gastrointestinal Symptom Severity
Checklist, which is designed similarly
to validated Gastrointestinal Symptom
Rating Scale but expanded to include
additional symptoms that may not be
captured by the Gastrointestinal
Symptom Rating Scale.10 In addition,
on the Gastrointestinal Symptom
Severity Checklist each subject is
asked to rate one symptom at a time
on a visual analog scale from 0 to 10,f Nutrition and Dietetics. This is an open access
Y-NC-SA license (http://creativecommons.org/
Table 1. Demographic characteristics of a cohort of 50 patients with inﬂammatory bowel disease in remission following the
Speciﬁc Carbohydrate Diet
Case
no. Disease Location Age Sex
Duration
of disease
(mo)
Duration
of diet
(mo)
Level of
education
Forbidden
food(s) Medication(s)
1 UCa Pancolitis 56 Mb 288 76 College None LDNc
2 UC Rectosigmoid 56 Fd 384 216 College None None
3 UC Pancolitis 41 F 36 9 College None Mesalamine (Asacole), LDN,
azathioprine
4 UC Rectosigmoid 35 F 108 82 College None LDN
5 UC Rectosigmoid 38 F 204 40 College None Mesalamine suppositories
6 UC Rectosigmoid 41 M 48 13 Graduate
degree
None Mesalamine (Lialdaf),
mesalamine enema
7 UC Rectosigmoid 32 F 132 7 College None Inﬂiximab
8 UC Proctitis 35 M 24 4 Graduate
degree
None Mesalamine (Lialda)
9 UC Pancolitis 25 F 324 2 Graduate
degree
None Prednisone (1 mg),
sulfasalazine (Azulfadineg),
mesalamine enema
10 CDh Ileocolonic 29 M 324 19 Graduate
degree
None Mesalamine (Pentasai),
inﬂiximab
11 CD Colonic 61 F 36 10 High
school
None Mesalamine
12 CD Colonic 48 M 24 6 Graduate
degree
None None
13 CD Ileocolonic 27 M 156 8 College None Adalimumab, LDN,
budesonide
14 CD Colonic 40 F 72 60 Graduate
degree
Chocolate None
15 CD Upper GIjþcolonic 10 M 60 39 Middle
school
Ice cream None
16 CD Upper
GIþileocolonic
11 F 24 8 Middle
school
Rice Mesalamine (Asacol)
17 CD Ileocolonic 31 F 156 14 College None Prednisone (1.5 mg),
inﬂiximab, LDN
18 CD Upper
GIþileocolonic
11 M 24 7 Middle
school
None None
19 CD Upper
GIþileocolonic
9 M 84 66 Middle
school
None None
20 CD Ileum 52 M 36 14 College None Mesalamine (Pentasa)
21 CD Upper GIþileum 49 M 384 5 College None None
22 CD Ileocolonic 41 M 192 31 College None Balsalazide
23 CD Upper GIþcolonic 13 F 36 14 Middle
school
Cream, canned
vegetables,
eucharist host
None
24 CD Ileocolonic 44 M 348 72 College Coffee None
25 CD Colonic 19 F 24 1 College None None
(continued on next page)
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Table 1. Demographic characteristics of a cohort of 50 patients with inﬂammatory bowel disease in remission following the
Speciﬁc Carbohydrate Diet (continued)
Case
no. Disease Location Age Sex
Duration
of disease
(mo)
Duration
of diet
(mo)
Level of
education
Forbidden
food(s) Medication(s)
26 CD Colonic 37 F 36 16 Graduate
degree
None None
27 CD Ileum 65 M 420 132 Graduate
degree
None Mesalamine (Asacol),
mesalamine enema,
colestipol
28 CD Ileocolonic 49 F 120 12 College Espresso 6-MPk
29 CD Colonic 44 M 300 2 College None None
30 CD Colonic 30 F 36 14 College Coconut water,
chocolate
Mesalamine (Lialda)
31 CD Ileocolonic 31 F 132 111 College None None
32 CD Colonic 39 M 276 158 Graduate
degree
Salad dressing None
33 CD Ileocolonic 58 F 384 24 Graduate
degree
None LDN
34 CD Ileum 51 F 48 6 Graduate
degree
None None
35 CD Colonic 43 F 24 9 College None None
36 CD Colonic 29 F 36 17 College Potatoes None
37 CD Upper GIþileum 19 M 36 13 High
school
Brown rice, corn 6-MP
38 CD Upper GIþcolonic 52 F 168 162 College Matzah once a
year
None
39 CD Colonic 42 F 48 10 Graduate
degree
None Mesalamine (Asacol)
40 CD Colonic 49 F 24 4 College None Mesalamine (Lialda)
41 CD Colonic 59 F 84 12 College Milk, candy,
cookies
Mesalamine (Lialda)
42 CD Ileocolonic 11 F 24 8 Middle
school
None Loperamide (Imodium)
43 CD Ileocolonic 15 F 12 6 High
school
None Mesalamine (Asacol), 6-MP
44 CD Gastric 12 M 36 22 Middle
school
School lunches None
45 CD Ileocolonic 29 M 60 60 Graduate
school
None LDN, adalimumab
46 IDl Sigmoid to distal
transverse, rectal
sparing
31 F 84 6 Graduate
degree
None Mesalamine (Asacol)
47 ID Right colon 17 M 60 8 High
school
Corn tortillas,
potatoes
Methotrexate
48 ID Rectosigmoid 56 F 48 16 College None None
(continued on next page)
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Table 1. Demographic characteristics of a cohort of 50 patients with inﬂammatory bowel disease in remission following the
Speciﬁc Carbohydrate Diet (continued)
Case
no. Disease Location Age Sex
Duration
of disease
(mo)
Duration
of diet
(mo)
Level of
education
Forbidden
food(s) Medication(s)
49 ID Pancolitis, sparing
rectum
39 M 240 72 Graduate
degree
Spelt bread, raw
milk, baked
goods
None
50 ID Right colon,
rectosigmoid
46 M 108 48 College Pizza Hydrocortisone enema
aUC¼ulcerative colitis.
bM¼male.
cLDN¼low-dose naltrexone.
dF¼female.
eAsacol (Warner Chilcott Company, LLC).
fLialda (Shire US, Inc).
gAzulfadine (Pﬁzer, Inc).
hCD¼Crohn’s disease.
iPentasa (Shire US, Inc).
jGI¼gastrointestinal.
k6-MP¼6-mercaptopurine.
lID¼indeterminate colitis.
PRACTICE APPLICATIONSwith higher scores corresponding to
increasing severity and frequency of
the symptom. The subject’s quality of
life was assessed by a validated in-
strument, the Short Quality of Life in
Inﬂammatory Bowel Disease Ques-
tionnaire (SIBDQ).11 Subjects also
rated their self-adherence to the SCD
and the effectiveness of the SCD on a
visual analog scale of 0% to 100%.
Subjects were included in the study
if they had documented IBD by a
physician within the United States and
reported to follow the SCD. All di-
agnoses of IBD were conﬁrmed by re-
view of endoscopy, radiology, and
pathology reports by a board-certiﬁed
gastroenterologist who specializes in
IBD at Rush University. Remission was
deﬁned as a Harvey-Bradshaw Index
<5 for CD and St Mark’s Index <4 for
UC. Both surveys needed to reﬂect
remission for ID.
Ethical Considerations
The Rush University Medical Center
Institutional Review Board approved
the study protocol and all participants
provided written informed consent
(and child assent, if appropriate).
INTERVENTION RESULTS
We obtained data on 50 cases in
remission: 36 subjects had CD, 9 sub-
jects had UC, and 5 subjects had ID. The
subject demographic characteristicsAugust 2015 Volume 115 Number 8and disease locations are given in
Table 1. The mean age was 36 years
(range¼10 to 66 years). Twenty-nine
subjects (58%) were female. Of pa-
tients with CD, the most highly repre-
sented subtype was colonic disease in
16 patients (three of whom also had
upper GI involvement) and ileocolonic
disease in 14 patients (three of whom
also had upper GI involvement). Of the
patients with UC, six had left-sided
disease and two had pancolitis. All
subjects were in remission: the mean
Harvey Bradshaw Index was 0.9
(range¼0 to 4) and the mean St Mark’s
Index was 1.4 (range¼0 to 3).
The mean GSSC score was 27.1 for
CD, 25.9 for UC, and 13.6 for ID
(range¼0 to 144), reﬂecting mild
gastrointestinal symptoms. The indi-
vidual symptom scores are shown in
Table 2.
Patients following the SCD in remis-
sion had a high quality of life with a
mean SIBDQ score of 60.9 (range¼35 to
70). The results for the subscales of
SIBDQ are given in Table 3.
The breakdown of medication use
among the subjects with CD and UC are
given in Table 1. In the CD group, eight
subjects were taking immunosuppres-
sive medications and only one patient
was not steroid-free and was taking
prednisone at a dose of 1.5 mg daily.
Nineteen subjects with CD were not
taking any medications for their IBD.JOURNAL OF THE ACADEPast medication use in this group
before starting the diet included
mesalamine-based drugs in 15 sub-
jects, prednisone in 12 subjects, bude-
sonide in two subjects, 6-MP in four
subjects, inﬂiximab in one subject,
certolizumab in one subject, ciproﬂox-
acin in four subjects, and metronida-
zole in six subjects. In the UC group,
three patients were taking immuno-
suppressive agents and only one pa-
tient was not steroid-free and was
taking prednisone at a dose of 1 mg
daily. One subject with UC was not
taking any medications. Prior use of
medications in this subject included
prednisone, 5-aminosalicylates, and
6-MP. In the ID group, one subject was
taking an immunosuppressive agent.
Two subjects with ID were taking no
medications. Prior use of medications
in this group included prednisone and
mesalamine drugs in both subjects and
inﬂiximab and ciproﬂoxacin in one
subject. Therefore, out of 22 patients
who were taking no medications at all,
16 had discontinued all steroids (14
were taking prednisone and two were
taking budesonide), three had dis-
continued TNF inhibitors, and ﬁve had
discontinued 6-MP and had remained
in remission.
The mean time the SCD was followed
was 35.4 months (range¼1 to 216
months). Forty-four subjects (88%) re-
ported eating the SCD yogurt, 33 ofMY OF NUTRITION AND DIETETICS 1229
Table 2. Gastrointestinal Symptom Severity Checklist (GSSC) results for cohort of 50 patients with inﬂammatory bowel disease in
remission following use of the Speciﬁc Carbohydrate Diet
GSSC item
Crohn’s Disease
(n[36)
Ulcerative Colitis
(n[9)
Indeterminate Colitis
(n[5)
% >0 Mean % >0 Mean % >0 Mean
Upper abdominal pain or discomfort 27.8 0.6 33.3 0.7 20.0 0.2
Lower abdominal pain or discomfort 44.4 0.8 55.6 1.4 20.0 0.2
Upper abdominal cramping 16.7 0.4 11.1 0.1 0 0
Lower abdominal cramping 22.2 0.4 22.2 0.6 0 0
Pain associated with eating 11.1 0.4 22.2 0.4 0 0
Bloating 30.6 1.3 33.3 1.2 40.0 0.8
Belching 33.3 0.7 33.3 0.6 20.0 0.4
Passing gas 66.7 1.8 77.8 2.2 40.0 0.6
Excessive gas overall 38.9 1.2 66.7 1.2 20.0 0.2
Heartburn 16.7 0.6 33.3 0.7 20.0 1.6
Indigestion 13.9 0.3 33.3 0.7 0 0
Nausea 13.9 0.6 22.2 0.6 20.0 0.4
Nausea associated with eating 13.9 0.5 11.1 0.3 20.0 0.4
Frequent bowel movements 13.9 0.9 33.3 0.6 20.0 0.2
Vomiting 13.9 0.4 0 0 0 0
Alternating bowel movements between
constipation and diarrhea
22.2 0.4 33.3 0.8 20.0 0.2
Constipation >70% of the time 22.2 0.5 11.1 0.3 0 0
Diarrhea >70% of the time 33.3 1.0 11.1 0.1 0 0
Irregular bowel habits 30.6 0.8 33.3 0.4 20.0 0.2
Infrequent bowel movements 27.8 0.5 33.3 0.7 0 0
Hard stools 36.1 1.0 33.3 0.7 20.0 0.4
Watery stools 47.2 1.6 44.4 0.9 20.0 0.6
Soft stools 41.7 1.6 66.7 3.6 60.0 1.4
Passage of mucous in the stool 19.4 0.5 33.3 1.3 20.0 0.2
Passage of blood in the stool (without
presence of hemorrhoids)
27.8 0.8 33.3 0.8 20.0 0.2
Straining with bowel movements 38.9 0.9 11.1 0.4 0 0
Fecal urgency 41.7 1.4 66.7 1.1 40.0 1.0
Bowel incontinence 13.9 0.5 0 0 0 0
Sensation of incomplete emptying of bowels 38.9 0.7 55.6 0.8 20.0 0.2
Loss of appetite 11.1 0.5 22.2 0.2 0 0
Weight loss 27.8 0.9 55.6 1.8 40.0 1
Decreased food intake because of symptoms 13.9 0.6 11.1 0.1 0 0
Difﬁculty swallowing 2.8 0 0 0 0 0
Pain with swallowing 0 0 0 0 0 0
Food coming up to mouth 2.8 0.1 0 0 0 0
Acid taste in mouth 5.6 0.1 0 0 20.0 1.6
Intolerance to multiple foods 38.9 1.8 33.3 0.7 20.0 1.6
Overall 86.1 27.1 88.9 25.9 80.0 13.6
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Table 3. Short Quality of Life in Inﬂammatory Bowel Disease Questionnaire
(SIBDQ) of a cohort of 50 patients in remission following use of the Speciﬁc
Carbohydrate Diet
Patient’s condition
SIBDQ Subscale Scores (mean–standard deviation)
Bowel Systemic Emotional Social Total
Overall (n¼50) 18.92.4 11.72.2 16.73.3 13.51.1 60.96.5
Crohn’s disease (n¼36) 18.82.6 11.92.1 16.63.5 13.51.3 60.96.9
Ulcerative colitis (n¼9) 18.42.1 11.32.3 16.72.7 13.40.9 59.95.7
Indeterminate colitis
(n¼5)
20.40.9 11.62.9 17.23.4 14.00.0 63.24.3
PRACTICE APPLICATIONSwhom (67%) ate it daily. Twenty-six
subjects (52%) reported using a sup-
plementary probiotic. The most com-
mon probiotics used were Lactobacillus
and Acidophilus species (13 CD patients
and four UC patients) and Saccharo-
myces boulardii preparations (4 CD pa-
tients and one UC patient).
Patients’ self-rating of compliance
with the SCD diet on a visual analog
scale of 0% to 100% had a mean
adherence rating of 95.2% (range¼71%
to 100%). The Figure shows an example
of a 3-day diet diary of one of the
subjects in the study that is an accurate
representation of the foods allowed on
the SCD. Although the diet requires
strict adherence, there were still 16Day 1
Breakfast 2 eggs, yogurt with far
Lunch Cube steak, apples, gre
Dinner Steak, carrots, green be
Snacks Grape juice, gelatin, pe
Day 2
Breakfast 2 eggs, yogurt with far
Lunch Steak, apples, asparagu
Dinner Turkey burger (no bun
Snacks Peanut butter brownie
Day 3
Breakfast 3 eggs, yogurt, honey
Lunch Chicken thighs, asparag
Dinner Pork with pineapple, ca
Snacks Peanut butter brownie
Figure. Actual 3-day food diary for one pat
Diet demonstrating a representative menu.
August 2015 Volume 115 Number 8subjects (32.1%) (12 CD patients and
four ID patients) who reported occa-
sional ability to eat some “forbidden”
foods (Table 1). Of these 16 subjects, 14
had CD and two had ID. All subjects
were eating SCD yogurt and had been
following the SCD diet for at least 8
months. Seven (43.7%) of these 16 pa-
tients who were eating “forbidden”
foods were also taking some type of
maintenance medication (Table 1).
Table 4 shows the reasons that pa-
tients started the SCD. Forty-one pa-
tients (82%) reported that one of the
reasons they started the diet was fear
of long-term consequences of medica-
tions. Other common reasons included
the belief that the SCD was moremer’s cheese, honey
en beans, carrots
ans
anut butter brownies, apples
mer’s cheese, honey
s
), apples, carrots, boiled shrimp
s, grape juice
us, baked apples, honey
rrots, asparagus, peaches
s, grape juice
ient following the Speciﬁc Carbohydrate
JOURNAL OF THE ACADEeffective than medications (64%),
medications were not effective (64%),
adverse reaction from a prior medica-
tion (56%), and recommendations from
Internet forums (44%).
Mean time for food preparation per
week was 10.8 hours (range¼0 to 32
hours). Twenty-four (58.5%) of 41 adult
subjects were able to hold full-time jobs
while implementing the diet. Mean
time to see some improvement when
following the SCD was 29.2 days
(range¼1 to 180 days). Thirty-three
subjects (66%) noted complete symp-
tom resolution, which did not occur until
a mean of 9.9 months (range¼1 to 60
months) after starting the SCD. Patients’
self-report of the effectiveness of the
SCD was obtained via visual analog
scales: SCD was rated as a mean of 91.3%
effective in controlling acute ﬂare
symptoms (range¼30% to 100%) and a
mean of 92.1% effective at maintaining
remission (range¼53% to 100%). Subjects
reported a mean of 40% difﬁculty rating
in following the diet (range¼0% to 100%).DISCUSSION AND LESSONS
LEARNED
This is the ﬁrst clinical description of
a large series of patients with IBD
following the SCD. Our survey results
suggest that SCD can potentially be an
effective tool in the management of
some patients with IBD and speciﬁcally
in patients with colonic and ileocolonic
CD who made up the majority of our
study group. A highly educated group
of patients follow the SCD; all but one
of the adults in our study had a college
or graduate degree. Our results also
suggest that in some patients with
moderate to severe disease who follow
this diet, discontinuation of immuno-
suppressive agents has been feasible.
One of the strengths of our study is
the veriﬁcation of the diagnosis of
IBD in all of the patients with medical
record reviews by an experienced
gastroenterologist who specializes in
IBD. Our limitations include the choice
of our subjects, all of whom were in
remission, biasing our ﬁndings toward
including patients with IBD who have
beneﬁted from SCD and were following
it for months. Nevertheless, we now
show that at least a subgroup of pa-
tients with IBD may notably improve
as a result of following the SCD and/or
dietary interventions in general. Our
ﬁndings enhance those of prior limitedMY OF NUTRITION AND DIETETICS 1231
Table 4. Reasons reported by cohort of 50 patients with inﬂammatory bowel
disease in remission for choosing to implement the Speciﬁc Carbohydrate Diet
(SCD)
Reason Cases (n) %
Fear of long-term consequences of medications 41 82
Efﬁcacy of SCD compared with medications 32 64
Medications not effective 32 64
Adverse reactions to medications 28 56
Recommendation from Internet forum 22 44
Recommendation from family/friends 15 30
Breaking the Vicious Cycle book7 4 8
Cost of medications 1 2
Seeking alternative treatment to medications 1 2
Fear of need for surgery 2 4
Fear of colon cancer 1 2
PRACTICE APPLICATIONScase reports of dietary therapy
with SCD and other dietary in-
terventions.12-16 Other, more long-term
diet interventions that are not SCD
have shown promise in a very limited
number of subjects.17,18
Further evidence suggesting diet can
be an effective treatment for some pa-
tients with IBD stems from the fact that
diet has the potential to change the
intestinal luminal environment, spe-
ciﬁcally the intestinal microbiome. Our
prior preliminary ﬁndings19,20 hint at a
change in the microbiome of patients
with IBD who follow the SCD. If
following the SCD changes the micro-
biome signiﬁcantly and/or reverses
some of the dysbiosis reported in pa-
tients with IBD, this may be a low-cost
intervention to induce and maintain
remission with little or no known
adverse reactions. As such, further
interventional studies of SCD and diet
therapies in general for IBD are ur-
gently needed.1232 JOURNAL OF THE ACADEMY OF NUTRIReferences
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